Empagliflozin,improved exercise tolerance and LV functional parameters in rats with CHF in the absence of metabolic disorders.The effect of empagliflozin on LV remodeling requires further study.

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-A-038-Tuesday
• By: IVKIN, Dmitry (Saint-Petersburg State Chemical-Pharmaceuitical Academy, Center of Experimental Pharmacology, Saint-Petersburg, Russian Federation)
• Co-author(s): Dmitry Ivkin: Center of Experimental Pharmacology, Saint-Petersburg State Chemical-Pharmaceuitical Academy, Saint-Petersburg, Russian Federation
  Sergey Okovityi: Saint-Petersburg State Chemical-Pharmaceuitical Academy, Saint-Petersburg, Russian Federation
  Marina Krasnova: Center of Experimental Pharmacology, Saint-Petersburg State Chemical-Pharmaceuitical Academy, Saint-Petersburg, Russian Federation
  Andrey Karpov: First Pavlov State Medical University of St. Peterburg, Saint-Petersburg, Russian Federation
  
• Abstract:

  Backgrounds

  EMPA-REG OUTCOME trial results shows that empagliflozin significantly decrease the heart failure hospitalization in patients with type 2 diabetes. 

  Aims

  To evaluate in experimental setting the efficacy of empagliflozin, for treatment of chronic heart failure (CHF) in the absence of carbohydrate metabolic disorders.  

  Methods

  CHF was modeled
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login